Verified Accreditation · Finland & Korea Focus · Egypt Price Tiers · v3.0
All verified: accredited laboratories from countries with strong medical regulatory foundations. Includes 🇰🇷 South Korea (global genomics hub), 🇩🇪 Germany · 🇫🇮 Finland (via Medicover Genetics), and leading European labs. Priced for Egypt's market.
Combines 16S + shotgun metagenomic NGS with AI bioinformatics. Unique combined DNA + gut microbiome kit in one saliva/stool sample. ISO 27001 and CE certified. Expanded to 10+ EU countries in 2025. Population-level comparison reports. Founded 2013 by Sergey Musienko and Artem Rudy. B2B distribution and white-label available.
World's ONLY doubly ISO-certified microbiome company (ISO 9001 + ISO 13485 medical device standard — no other microbiome lab holds this). Active partner program: commission, co-marketing, training. Species-level 16S rRNA + metabolic pathway predictions. Parent BiomeDx developing cancer microbiome diagnostics. Ideal first B2B partner — lowest regulatory risk for Egyptian physicians.
German precision gut microbiome under strict EU MDR and German medical device regulation. INTEST·pro: 16S V3-V4 profiling with disease risk assessment and multi-language nutrition plans. European biotech award winner. Reseller/distribution B2B model. Multi-language report platform — Arabic localization feasible. Berlin HQ for direct meetings.
One of Europe's most comprehensively accredited genetic and microbiome laboratories: CAP + ISO 15189 + ISO 9001 + ISO 13485 + GMP + GCP. 25+ years experience. Operates as Fimlab Laboratories' sole genetic testing partner in Finland (selected after competitive tender). Offers ebiom+ endometrial microbiome analysis. Unique Technology Transfer Platform — enables Egyptian lab to perform tests in-house. Already expanding across Africa. Attended WHX Labs Dubai 2026.
Validated CE-IVD microbiome diagnostic tools for IBD, colorectal cancer risk, and metabolic disorder panels. Received 2025 commercialization financing. Bridges consumer wellness and clinical diagnostics. Norway's stringent healthcare standards — EEA medical device regulation compliance. Perfect clinical positioning match for ماس التشخيصية's dry lab model.
Pure B2B microbiome white-label technology platform — partners use any local lab + InnerBuddies AI algorithms. White-label launch under 30 days, no minimum volumes. GDPR, HIPAA, and ISO compliant. Supports 16S and shotgun metagenomics. Built exclusively for clinic and lab resellers. Lowest-cost entry to microbiome reporting — ideal for Egypt's price-sensitive market.
South Korea's leading CAP-accredited clinical genomics company, subsidiary of GC Group (one of Korea's largest healthcare conglomerates). CAP accredited + Korea MFDS (Ministry of Food and Drug Safety) NGS clinical laboratory certified. Offers GeneCheck wellness SNP test and "Genome Health" wellness panel. Signed exclusive B2B agreement with Thai partner (MP Group, 2023) — exact model applicable to Egypt. Actively seeking MENA distribution partners. Competitive Asian pricing ideal for Egypt.
South Korea's pioneering clinical genomics and microbiome laboratory since 1997. ISO 15189 + CAP accredited. WGS, WES, NGS panels, 16S and full shotgun metagenomics. CE-marked collection kits. European office in Amsterdam. Processes internationally shipped samples with fast turnaround. Active GCC-region expansion interest. One of the largest sequencing service companies globally by volume.
World's largest genomics service company by sequencing capacity. European HQ at 25 Milton Road, Cambridge, UK (adjacent to Wellcome Genome Campus). ISO 17025 + CAP certified. WGS, WES, RNA-seq, 16S rRNA, and full shotgun metagenomics. 3,500+ partner institutions in 80+ countries. Dedicated AMEA (Africa/Middle East/Asia) regional team. Most competitive pricing in the market due to massive scale economies.
Clinical-grade 16S rRNA with dedicated practitioner portal and physician data exports. IBS, ME/CFS, and long-COVID specific microbiome panels. AI wellness analytics. Active partnership program for healthcare providers. Founded by Rose Walbrugh. UK GDPR compliant. Strong functional medicine physician base — directly analogous to ماس's clinical network model.
Verified accreditation · No Egypt presence · 🇫🇮 Finland genomics hub represented via Medicover Genetics (Fimlab Finland exclusive partner) · 🇰🇷 Korea via GC Genome (CAP + MFDS) · CircleDNA and Xcode Life excluded.
Europe's #1 preventive genetics platform. 35+ countries, 1,000+ medical centre partners. €20M Series B (BlackPeak Capital, 2025). 20+ AI wellness reports: diet, fitness, sleep, stress, ancestry, disease risk. WGS option. FT1000 fastest-growing EU company. Acquired New Era Genetics (Hungary, Feb 2026). ISO 27001 certified. Mid-range B2B pricing — accessible for Egypt's private healthcare sector.
CAP + ISO 15189 + ISO 13485 + GMP accredited. 25+ years in genetic medicine. Sole genetic testing partner of Fimlab Laboratories Finland (ISO/IEC 15189 accredited, Finland's largest lab network). Wellness portfolio: pharmacogenomics, hereditary cancer panels, carrier screening, NIPT (VERACITY). CE-IVD kits + Technology Transfer Platform enable Egyptian lab to test in-house. Already serving Africa and recently attended WHX Labs Dubai 2026. Partner with us page open.
GC Genome's "Gene Doctor" wellness SNP test and "Genome Health" panel offer affordable, physician-guided wellness genomics. CAP accredited + Korea MFDS (FDA equivalent) NGS certified — the only Korean lab with both. Subsidiary of GC Group (global healthcare). B2B model proven: signed exclusive wellness partnership with Thailand's MP Group (2023). Covers health checkup genomics, SNP-based metabolic/nutrition/fitness panels. Best price-to-accreditation ratio for Egypt.
WGS at accessible pricing for wellness, pharmacogenomics, and hereditary cancer. CLIA + CAP accredited — highest US regulatory standards applied to EU lab. 30x WGS with lifelong data reanalysis. White-label B2B genomics platform with physician portal. MENA market interest expressed. Premium positioning justified by clinical-grade accreditation — suitable for ماس's high-end oncology physician network.
2,000+ regional ancestry breakdowns worldwide including the most comprehensive MENA and North African reference populations of any genetics company — uniquely compelling for Egyptian patients who can see their own genetic heritage in detail. Combines ancestry with wellbeing insights. B2B licensing with competitive margin. Highly affordable entry price makes it accessible to Egypt's private pay segment.
Precision prevention company with CE-certified polygenic risk score (PRS) genetic tests for four major cancers: breast, prostate, colorectal, and melanoma. AnteBC breast cancer test validated on UK Biobank + Estonian Biobank data. Peer-reviewed publications (Breast Cancer: Basic and Clinical Research, 2023). Supported by EIT Health and Enterprise Estonia. Actively expanding to new markets — actively seeking international B2B clinical partners. Highly relevant to Egypt's rapidly growing cancer screening awareness.
First company to deliver affordable clinical-grade WGS with physician-reviewed results at scale. European operations from Lisbon. Covers hereditary cancer, pharmacogenomics, rare disease, wellness, and cardiovascular risk. Physician-interpreted reports with genetic counselor consultation included in every test. B2B/hospital partnership model expanding across EU. Premium tier but clinically differentiated.
Pure white-label wellness genomics AI platform. Partners send raw SNP or WGS data — LifeNome generates 250+ trait branded reports. No minimum volumes, fast API + portal integration. Covers nutrition, fitness, skin, sleep, stress, pharmacogenomics. Fastest and most affordable path to a branded wellness genomics panel. Budget pricing ideal for launching Egypt's first private wellness genomics product at accessible price points.
All 2026 dates verified. Europe & Asia only — no Middle East events. Specifically selected for verified attendance by target labs including Korean genomics conferences.
World's most accessible premier genomics event. 180+ exhibitors, 5,000+ attendees. 90% free attendance policy. Medicover Genetics, Atlas Biomed, Dante Labs, Living DNA, Biomesight, LifeNome all exhibit or attend. Best single event to meet 6+ target labs — book 1:1 meetings via event matchmaking platform 4 weeks in advance.
Europe's most authoritative clinical and translational genetics conference. GenePlanet, Medicover Genetics, BIOMES NGS, Genetic Analysis AS, Antegenes, Dante Labs, Veritas Europe all present or exhibit. Commercial deals initiated in adjacent partner meetings. Attending signals ماس التشخيصية is a scientific partner, not just a distributor.
Structured B2B collaboration forum by Global Engage. Explicitly designed for partnership deals: structured 1:1 meetings, deal-flow sessions. Atlas Biomed, myBioma, BIOMES NGS, InnerBuddies, Biomesight, Omed Health participate. Intimate format (200–400 delegates) — highest partnership conversion rate of any microbiome event.
Asia's largest IVD exhibition — 23rd edition. Premier event to meet GC Genome (Korea), Macrogen (Korea), and Novogene reps. Korean and Chinese genomics labs actively seek MENA distribution partnerships at CACLP. Best venue to negotiate competitive Asian lab pricing for Egypt. 1,000+ exhibitors, 50,000+ attendees.
"Microbial Intelligence: Transforming Health, Ecosystems & Future Biotechnologies." Strong microbiome science track. Atlas Biomed, BIOMES NGS, Biomesight, Genetic Analysis AS, Medicover Genetics (ebiom+) present research. Excellent for scientific-level partnership conversations that lead to BD discussions.
ESHG-listed event in Berlin. BIOMES NGS HQ is Berlin-based — ideal for direct HQ meetings. Medicover Genetics Germany HQ also accessible. Combine conference attendance with bilateral meetings at BIOMES Berlin offices and GenePlanet's German distribution partners. Lower cost than major exhibitions.
Laboratory Medicine Congress + KSLM 67th Annual Meeting. GC Genome and Macrogen are both headquartered in the Seoul area — ideal for face-to-face BD meetings at their home event. Request formal partnership meetings at each company's HQ the day before the congress. Best single Korea trip for both target labs.
Asia's leading life sciences and biotech business conference. GC Genome, Macrogen, and Novogene AMEA all participate. Singapore serves as the ASEAN hub for Asian companies entering MENA markets — ideal for meeting regional BD directors who handle international expansion. Position ماس as the exclusive Egyptian gateway.
Europe's leading precision medicine conference. Futura Genetics (Swiss HQ), Veritas Europe, Dante Labs, GenePlanet senior commercial leaders attend. Smaller, more intimate format — C-suite access far easier than at large exhibitions. Combine with bilateral Swiss meetings at Futura Genetics HQ.
Wellcome Genome Campus — world's leading genomics research environment. Novogene Europe HQ is at 25 Milton Road Cambridge (walking distance). Atlas Biomed and Biomesight UK both within 1 hour. Plan a 3-day Cambridge science + partnership trip: conference + Novogene Europe HQ bilateral + Biomesight visit.
Curated approaches prioritizing accredited labs from strong medical countries, Korea genomics hub, Finland connections, and Egypt-appropriate pricing tiers.
Every lab on this curated list is from a country with strong medical regulatory foundations (Germany, UK, Finland, Austria, Norway, South Korea, Netherlands, Slovenia, Italy, Portugal, Estonia). Lead your outreach by mirroring their accreditation language: "your CAP/ISO certification aligns with our ISO-tracked dry lab workflows." This signals seriousness immediately.
Frame Egypt as an untapped exclusive territory with 106M people and zero established competition in every category. You are not asking to distribute their product — you are offering them Egypt. This framing flips the power dynamic: they need you to enter the market, not the other way around.
Start your Asian BD tour with GC Genome and Macrogen — both CAP accredited, both from South Korea's globally recognized genomics hub, both at $70–160/test B2B pricing. GC Genome already signed an exclusive B2B deal with Thailand using the exact model you are proposing for Egypt. This is a proven, replicable playbook.
The strongest Finland connection is through Medicover Genetics — sole genetic testing partner of Fimlab Laboratories (Finland's largest healthcare lab, ISO/IEC 15189 T043 accredited). Medicover Genetics attended WHX Labs Dubai 2026, signaling active MENA expansion. Their Technology Transfer Platform is uniquely valuable — enables ماس to test in-house.
Lead every approach with the AstraZeneca Egypt partnership as the first credential. International labs — especially ISO/CAP-accredited European ones — are wary of unknown MENA distributors. A live Big Pharma partnership signals compliance infrastructure, a real clinical pipeline, and bankable institutional credibility in 10 seconds.
Don't ask for exclusivity on first contact. Propose: "Let's run 50 tests in 90 days and measure physician adoption." This dramatically lowers friction for any lab's commercial team. Labs will agree to a revenue-generating pilot when they'd hesitate at a full distribution agreement. Convert pilots into exclusive contracts based on results.
Egypt needs a tiered portfolio: Budget (GC Genome, Macrogen, Novogene, InnerBuddies, LifeNome, Living DNA) for broad physician outreach; Mid-range (myBioma, GenePlanet, BIOMES, Atlas Biomed, Medicover, Antegenes) for specialist clinics; Premium (Dante Labs, Veritas Genetics) for university hospitals and oncology centers. Don't pitch the same product to all segments.
The October LMCE Seoul conference is your single highest-ROI Asia trip: attend the conference, then request formal partnership meetings at GC Genome HQ (Yongin, 40min from Seoul) and Macrogen HQ (Seoul). Two CAP-accredited Korean labs, one trip, two formal meetings — this is the Korea BD strategy in one sentence.
For European labs (Medicover Genetics, Veritas Genetics, Antegenes, Futura Genetics) requiring physician-interpreted or counselor-accompanied results, the DOCGene telemedicine platform is your answer. Position it explicitly: "DOCGene eliminates the physical counselor-presence requirement — you get Egyptian compliance without a local presence." This is a genuine competitive advantage vs any other MENA distributor.